Concise Prescribing Info
Dosage/Direction for Use
Adult : PO 50-100 mg 2-3 times/day.
Dosage Details
Adult: 50-100 mg 2-3 times daily.
Renal Impairment
Contraindicated in marked renal impairment.
Hepatic Impairment
Contraindicated in marked hepatic impairment.
Na or K depletion, adrenal gland failure, hyperchloraemic acidosis, and hepatic cirrhosis. Marked hepatic or renal impairment. Not to be used for long-term treatment of angle-closure glaucoma.
Special Precautions
Patient w/ pulmonary obstruction or emphysema, prediabetes or DM. Pregnancy and lactation.
Adverse Reactions
Paraesthesia, hearing dysfunction or tinnitus, fatigue, malaise, loss of appetite, taste alteration, GI disturbances (e.g. nausea, vomiting, diarrhoea), polyuria, drowsiness, confusion, metabolic acidosis, electrolyte imbalance, transient myopia, urticaria, melaena, haematuria, glycosuria, hepatic insufficiency, flaccid paralysis, photosensitivity, convulsions. Rarely, crystalluria and renal calculi.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, and other blood dyscrasias.
Monitor CBC, platelet count and serum electrolytes periodically.
Drug Interactions
Concomitant use w/ high-dose aspirin may result to anorexia, tachypnoea, lethargy, coma and death. Concomitant use w/ steroids may result to hypokalaemia.
Description: Methazolamide inhibits carbonic anhydrase resulting to decreased secretion of aqueous humour, thus decreasing intraocular pressure.
Onset: 2-4 hr.
Duration: 10-18 hr.
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 1-2 hr.
Distribution: Distributed throughout the body including the plasma, CSF, aqueous humour of eye, RBC, bile and extra-cellular fluid. Volume of distribution: 17-23 L. Plasma protein binding: Approx 55%.
Metabolism: Partially metabolised hepatically.
Excretion: Via urine (approx 15-30%). Elimination half-life: Approx 14 hr.
Chemical Structure

Click on icon to see table/diagram/image
Store between 15-30°C.
Disclaimer: This information is independently developed by MIMS based on Methazolamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in